Baltimore, Maryland
Phase 3 cancer trials in Baltimore, MD
71 Phase 3 cancer studies are recruiting participants at sites in Baltimore as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Baltimore at a glance
- 71 studies are recruiting at a site in Baltimore.
- By phase: Phase 2/3 (4), Phase 3 (67).
- By sponsor: industry (41), university, hospital or other (22), government (8).
- By research area: Breast Cancer (22), Lung Cancer (18), Prostate Cancer (12), Lymphoma (11), Pancreatic Cancer (6), Melanoma (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Baltimore
Basic details from each study's public record (the 30 most recently updated of 71). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Greater Baltimore Medical Center · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT07391774 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- MedStar Franklin Square Medical Center ( Site 0031) · MedStar Good Samaritan Hospital ( Site 0079)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mercy Medical Center - Baltimore ( Site 0015)
- Registry record
- NCT06966700 · updated
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Johns Hopkins Kimmel Cancer Center
- Registry record
- NCT05696626 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · Mercy Medical Center · Sinai Hospital of Baltimore
- Registry record
- NCT06058377 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins
- Registry record
- NCT06982521 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study sites
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center · Sinai Hospital of Baltimore, Inc. · St. Agnes Hospital
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Greater Baltimore Medical Center · Johns Hopkins University/Sidney Kimmel Cancer Center · Kaiser Permanente-Woodlawn Medical Center
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Kaiser Permanente-Woodlawn Medical Center · Maryland Proton Treatment Center · MedStar Franklin Square Medical Center/Weinberg Cancer Institute
- Registry record
- NCT06748222 · updated
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- University of Maryland
- Registry record
- NCT06790693 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Lung cancer studies recruiting in Baltimore
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Greater Baltimore Medical Center · Johns Hopkins University/Sidney Kimmel Cancer Center · Kaiser Permanente-Woodlawn Medical Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT06096844 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study site
- Ascension Saint Agnes Hospital
- Registry record
- NCT06472245 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- University of Maryland School of Medicine
- Registry record
- NCT07472517 · updated
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Saint Agnes Hospital - Baltimore - Hunt - PPDS
- Registry record
- NCT06793215 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Johns Hopkins Bayview Medical Center
- Registry record
- NCT06119581 · updated
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Johns Hopkins Bayview Medical Center · University of Maryland
- Registry record
- NCT06890598 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Prostate cancer studies recruiting in Baltimore
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT04423211 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Baltimore Veterans Affairs Medical Center ( Site 0069) · Greenebaum Comprehensive Cancer Center ( Site 0049)
- Registry record
- NCT06136624 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Johns Hopkins University
- Registry record
- NCT07164443 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Lymphoma studies recruiting in Baltimore
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06337318 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06724237 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT05675410 · updated
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of Maryland Greenebaum Comprehensive Cancer Center
- Registry record
- NCT06091865 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT03150693 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Baltimore, MD on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Baltimore
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Johns Hopkins University
- Registry record
- NCT07621718 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Ask about studies near Baltimore
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections